目的 构建包载芳烃受体抑制剂CH223191的酶敏感多肽胶束并对其进行表征,初步评估此多肽胶束向T细胞递送药物的可行性。方法 采用固相合成法合成了序列为stearyl-HHHRRRRRPLGLAGK-(Mal)的多肽(SHRP)。制备了载药胶束SHRP-CH,测定了其粒径、载药量、临界胶束浓度等,评价其细胞毒性及免疫原性,并使用流式及激光共聚焦考察了CD8+T细胞对胶束的摄取效率。结果 SHRP-CH的粒径为(133.8±7.4)nm,酶处理后粒径减少为(92±5.8)nm,载药量和包封率分别为(7.1±1.2)%、(67.7±2.3)%,酶解前后的胶束均具备较低的细胞毒性;CD8+T细胞摄取实验证实了此胶束体系向T细胞递送药物的可行性。结论 SHRP多肽酶敏感胶束体系具有较好的载药能力及低细胞毒性,有希望成为T细胞药物递送的潜在载体。
Abstract
OBJECTIVE To construct and characterize an enzyme-sensitive poly-peptide micelles which carrying the aromatic hydrocarbon receptor inhibitor CH223191, and preliminary evaluate its feasibility of delivering drugs to T cells. METHODS The peptide monomer SHRP was synthesized by solid-phase synthesis and the drug-loaded micelle SHRP-CH was prepared. Its particle size, drug loading, critical micelle concentration, cytotoxicity and immunogenicity etc. were measured. Flow cytometry and laser confocal were used to investigate the uptake efficiency of micelles into CD8+T cells. RESULTS The particle size of SHRP-CH was (133.8±7.4) nm, the particle size reduced to (92±5.8) nm after enzyme treatment; drug loading and encapsulation rate were (7.1±1.2)% and (67.7±2.3)%, micelles before and after enzymatic hydrolysis both have low cytotoxicity; CD8+T cell uptake experiments confirmed the feasibility of this micelle system to deliver drugs to T cells. CONCLUSION SHRP peptide micelle system has good drug-carrying capacity and low cytotoxicity, and is expected to be a potential carrier for T-cell drug delivery.
关键词
多肽 /
纳米胶束 /
CH223191 /
T细胞 /
免疫治疗
{{custom_keyword}} /
Key words
poly-peptide /
micelle /
CH223191 /
T cell /
immunotherapy
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] BYUN D J, WOLCHOK J D, ROSENBERG L M, et al. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies[J]. Nat Rev Endocrinol, 2017, 13(4): 195-207.
[2] PARDOLL D M. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264.
[3] CHAMPIAT S, LAMBOTTE O, BARREAU E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016, 27(4): 559-574.
[4] NAIDOO J, PAGE D B, LI B T, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2015, 26(12): 2375-2391.
[5] JEANBART L, BALLESTER M, DE TITTA A, et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes[J]. Cancer Immunol Res, 2014, 2(5): 436-447.
[6] SMITH T T, STEPHAN S B, MOFFETT H F, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers[J]. Nat Nanotechnol, 2017, 12(8): 813-820.
[7] HAGAN C T, MEDIK Y B, WANG A Z. Nanotechnology approaches to improving cancer immunotherapy[J]. Adv Cancer Res, 2018, 139: 35-56.
[8] GOLDBERG M S. Improving cancer immunotherapy through nanotechnology[J]. Nat Rev Cancer, 2019, 19(10): 587-602.
[9] CAI C, WANG L, LIN J. Self-assembly of polypeptide-based copolymers into diverse aggregates[J]. Chem Commun (Camb), 2011, 47(40): 11189-11203.
[10] ZAGORODKO O, ARROYO-CRESPO J J, NEBOT V J, et al. Polypeptide-based conjugates as therapeutics: opportunities and challenges[J]. Macromol Biosci, 2017, 17(1):Doi:10.1002/mabi.201600316.
[11] LEE D, NOH I, YOO J, et al. pH-controllable cell-penetrating polypeptide that exhibits cancer targeting[J]. Acta Biomater, 2017, 57: 187-196.
[12] LI G, GAO Y, GONG C, et al. Dual-blockade immune checkpoint for breast cancer treatment based on a tumor-penetrating peptide assembling nanoparticle[J]. ACS Appl Mater Interfaces, 2019, 11(43): 39513-39524.
[13] TAI Z, WANG X, TIAN J, et al. Biodegradable stearylated peptide with internal disulfide bonds for efficient delivery of siRNA in vitro and in vivo[J]. Biomacromolecules, 2015, 16(4): 1119-1130.
[14] YAO C, TAI Z, WANG X, et al. Reduction-responsive cross-linked stearyl peptide for effective delivery of plasmid DNA[J]. Int J Nanomed, 2015, 10: 3403-3416.
[15] HUANG J, XU Y, XIAO H, et al. Core-shell distinct nanodrug showing on-demand sequential drug release to act on multiple cell types for synergistic anticancer therapy[J]. ACS Nano, 2019, 13(6): 7036-7049.
[16] ZHAO B, DEGROOT D E, HAYASHI A, et al. CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor[J]. Toxicol Sci, 2010, 117(2): 393-403.
[17] LIU Y, LIANG X, DONG W, et al. Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation[J]. Cancer Cell, 2018, 33(3): 480-494 e487.
[18] BASU RAY G, CHAKRABORTY I, MOULIK S P. Pyrene absorption can be a convenient method for probing critical micellar concentration (cmc) and indexing micellar polarity[J]. J Colloid Interface Sci, 2006, 294(1): 248-254.
[19] KE W, LI J, ZHAO K, et al. Modular design and facile synthesis of enzyme-responsive peptide-linked block copolymers for efficient delivery of doxorubicin[J]. Biomacromolecules, 2016, 17(10): 3268-3276.
[20] KIM J H, KIM C S, IGNACIO R M, et al. Immunotoxicity of silicon dioxide nanoparticles with different sizes and electrostatic charge[J]. Int J Nanomed, 2014,9(suppl 2):183-193.
[21] SHI C, LIU T, GUO Z, et al. Reprogramming tumor-associated macrophages by nanoparticle-based reactive oxygen species photogeneration[J]. Nano Lett, 2018, 18(11): 7330-7342.
[22] YANG W, ZHU G, WANG S, et al. In situ dendritic cell vaccine for effective cancer immunotherapy[J]. ACS Nano, 2019, 13(3): 3083-3094.
[23] YANG Y S, MOYNIHAN K D, BEKDEMIR A, et al. Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles[J]. Biomater Sci, 2018, 7(1): 113-124.
[24] LIU Z, WINTERS M, HOLODNIY M, et al. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters[J]. Angew Chem Int Ed Engl, 2007, 46(12): 2023-2027.
[25] LI S Y, LIU Y, XU C F, et al. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation[J]. J Controlled Release, 2016, 231: 17-28.
[26] MAI Y, EISENBERG A. Self-assembly of block copolymers[J]. Chem Soc Rev, 2012, 41(18): 5969-5985.
[27] CHEN G, CHEN W, WU Z, et al. MRI-visible polymeric vector bearing CD3 single chain antibody for gene delivery to T cells for immunosuppression[J]. Biomaterials, 2009, 30(10): 1962-1970.
[28] SCHMID D, PARK C G, HARTL C A, et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity[J]. Nat Commun, 2017, 8(1): 1747.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金项目资助(81972891);国家自然科学青年科学基金项目资助(81803078);上海市科委基础研究项目资助(18JC1414200)
{{custom_fund}}
PDF(1878 KB)
